Search
GLP-1 Treatment Options
A collection of 63 research studies where GLP-1 is the interventional treatment. These studies are located in the United States. GLP-1 is used for conditions such as Obesity, Type 2 Diabetes and Myocardial Infarction.
61 - 63 of 63
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man
Unknown
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2015
Locations: ICON PLC, San Antonio, Texas
Conditions: Insulin Resistance
Dose-response Study of Exendin-9,39 on Glucose Metabolism
Completed
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a d... Read More
Gender:
ALL
Ages:
Between 20 years and 45 years
Trial Updated:
01/18/2013
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
GLP1R Polymorphisms and Response to GLP1
Completed
Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes. Furthermore GLP-1 based therapy is an important part of the therapeutic armamentarium for the treatment of type 2 diabetes. The GLP-1 receptor (GLP1R) is the principal site of action of GLP-1 and GLP-1 receptor agonists like exenatide and liraglutide. The gene coding for this recepto... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
12/14/2011
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Diabetes
61 - 63 of 63